EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer - ScienceDirect
Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion | BMC Cancer | Full Text
Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. - Abstract - Europe PMC
EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer - ScienceDirect
AddexBio Product Detail - A431 Cells
HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC
Epithelial‐mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4‐ALK translocation - Kim - 2013 - Molecular Oncology - Wiley Online Library
EMT changes and resistance to ALK-TKIs in H2228 cells exposed to... | Download Scientific Diagram
Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation - ScienceDirect
Response to an HSP90 inhibitor in H3122/CR and H2228/TR cell lines. (A)... | Download Scientific Diagram
![PDF] Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2b265c0fd1b06a512472598fe7575a0e724931a3/2-Figure1-1.png "PDF] Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells | Semantic Scholar")
PDF] Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells | Semantic Scholar
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1 | Oncogenesis
HUMAN IMPRINTING ENCYCLOPEDIA
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition | EMBO Molecular Medicine
JCRB Luciferase Expressing Cancer Cells :: NCI-H2228-Luc -
A549/DDP Cell Line - EP-CL-0519 | Civic Bioscience
PLOS ONE: Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3
Supplemental Materials for BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer - Lung Cancer
Establishment of ALK-TKI-resistant H2228 cells. (A) H2228-CRR,... | Download Scientific Diagram
Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Future Oncology
Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer - Annals of Oncology
Cells | Free Full-Text | Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement | HTML
EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer | bioRxiv
